Find the answers to your questions about non-Hodgkins lymphoma. To make the most of our extensive source, please choose the topic you like, and simply click.
Non-Hodgkin’s lymphoma (NHL) is one of the two most common types of lymphoma. It affects the immune system, and it starts with the proliferation of white blood cells in the immune system by mutating. However, the exact cause is unknown.
The lymphatic system or lymph system is an essential part of our immune system. It is a network of tubes and tissues that runs throughout the body. Working similarly to blood, it has an extensive network of vessels that run through nearly all of our tissues to allow the movement of lymph fluid. It maintains fluid balance in the body. It plays a role in absorbing fats and fat-soluble nutrients. And it also protects the body from disease by removing germs (bacteria, viruses, and parasites) toxins.
The lymphatic system contains lymph that carries white blood cells called lymphocytes.
These lymph types consist of:
Non-Hodgking’s lymphoma is much more common than the other types. It can include many different types of lymphoma that all share some of the same characteristics. Generally, it develops in lymph nodes, stomach, small intestine, bone marrow, lymph tissue, lymph nodes, and skin. Lymphoma cells can be seen in all body parts or a single area.
NHL occurs when mature B, T, and NK lymph cells in the lymphatic system mutate and grow uncontrollably. However, the most common type of NHL is B-cell lymphoma. If NHL is not treated, cancerous cells replace normal white cells, and the immune system cannot provide adequate protection against infection.
There are many different subtypes of NHL, either indolent (slow-growing) or aggressive (fast-growing). Two of the most frequently asked questions regarding lymphoma are “Is lymphoma a type of blood cancer?” and “Is lymphoma contagious?”. Lymphoma is a type of blood cancer and is not contagious. NHL is primarily seen in people aged 60-74 years.
The signs and symptoms of non-Hodgking’s lymphoma can be listed as follows;
Although most people diagnosed with NHL do not have obvious risk factors, some factors that can increase the risk of NHL include:
There are over 60 different types of lymphoma, which are sorted into groups or sub-types. The most common types are listed as follows:
Sources:
Non-Hodgkin’s lymphoma (NHL) is one of the two most common types of lymphoma. It affects the immune system, and it starts with the proliferation of white blood cells in the immune system by mutating. However, the exact cause is unknown.
The lymphatic system or lymph system is an essential part of our immune system. It is a network of tubes and tissues that runs throughout the body. Working similarly to blood, it has an extensive network of vessels that run through nearly all of our tissues to allow the movement of lymph fluid. It maintains fluid balance in the body. It plays a role in absorbing fats and fat-soluble nutrients. And it also protects the body from disease by removing germs (bacteria, viruses, and parasites) toxins.
The lymphatic system contains lymph that carries white blood cells called lymphocytes.
These lymph types consist of:
Non-Hodgking’s lymphoma is much more common than the other types. It can include many different types of lymphoma that all share some of the same characteristics. Generally, it develops in lymph nodes, stomach, small intestine, bone marrow, lymph tissue, lymph nodes, and skin. Lymphoma cells can be seen in all body parts or a single area.
NHL occurs when mature B, T, and NK lymph cells in the lymphatic system mutate and grow uncontrollably. However, the most common type of NHL is B-cell lymphoma. If NHL is not treated, cancerous cells replace normal white cells, and the immune system cannot provide adequate protection against infection.
There are many different subtypes of NHL, either indolent (slow-growing) or aggressive (fast-growing). Two of the most frequently asked questions regarding lymphoma are “Is lymphoma a type of blood cancer?” and “Is lymphoma contagious?”. Lymphoma is a type of blood cancer and is not contagious. NHL is primarily seen in people aged 60-74 years.
The signs and symptoms of non-Hodgking’s lymphoma can be listed as follows;
Although most people diagnosed with NHL do not have obvious risk factors, some factors that can increase the risk of NHL include:
There are over 60 different types of lymphoma, which are sorted into groups or sub-types. The most common types are listed as follows:
Sources:
The signs and symptoms for non-Hodgkin’s lymphoma (NHL) vary based on the type and location of the disease. Most of the symptoms associated with NHL can be caused by other conditions, such as influenza, mononucleosis, or infection as well, so the fact that you present them does not necessarily mean that you have lymphoma. But if the symptoms do not go away and instead make you feel more uncomfortable day by day, you should see a doctor.
Here are the common symptoms:
People with non-Hodgkin’s lymphoma might also present symptoms called B symptoms, including:
The root cause of weight loss might be classified into 3 categories: mental health conditions, digestion-related problems, and other physical health problems. Mental health-related problems can be listed as eating disorders, depression, and anxiety. Reducing or taking control of stress might be a good start to overcome if the problem is related to mental health. Problems such as coeliac disease and irritable bowel syndrome are categorized as digestion-related problems. The third category includes a wider range of physical problems varying from thyroid irregularity, heart problems, diabetes, and an enlarged spleen. The patient might be feeling full even after eating a small portion of food. It might be a sign of lymphoma in the abdomen. If the abdominal pain is accompanied by vomiting and nausea, it might be a sign of lymphoma in the stomach or intestines. Since it is not possible to identify the right cause of unintentional weight loss, lack of appetite, or swelling in the abdomen, people experiencing it are advised to have themselves checked by a medical professional.
Sources:
Non-Hodgkin’s lymphoma (NHL) is one of the most frequent cancers in the US, accounting for approximately 4 percent of all cancers. The following are the projections for non-Hodgkin’s lymphoma in 2022:
Overall, a man’s lifetime risk of developing NHL is about 1 in 42, while a woman’s risk is about 1 in 52. However, a variety of risk factors can influence everyone’s risk. NHL may strike at any age. It is, in fact, one of the most frequent cancers among children, adolescents, and young people.
Still, the risk of developing NHL increases throughout life, and more than half of patients are 65 or older at the time of diagnosis. The aging of the American population is likely to lead to an increase in NHL cases during the coming years.
It is estimated that 20,720 deaths (12,170 men and 8,550 women) from this disease will occur this year. It is the ninth leading cause of death from cancer in both men and women. Thanks to the advancements in treatment, the survival rate has been improving since 1997. From 2009 through 2018, the death rate fell by 2 percent every year.
The 5-year survival rate indicates the percentage of people who live for at least 5 years after being diagnosed with cancer. Percentage denotes how many out of a total of 100. The overall 5-year survival rate for NHL patients is 73 percent.
For stage I NHL, the 5-year survival rate is more than 83 percent. For stage II the 5-year survival rate is close to 76 percent and for stage III it is more than 70 percent. For stage IV NHL, the 5-year survival rate is around 63 percent. These survival rates vary depending on the cancer’s stage and subtype.
The rate of new cases of non-Hodgkin’s lymphoma was 19.6 per 100,000 men and women per year. The death rate was 5.3 per 100,000 men and women per year. These rates are age-adjusted and based on 2014–2018 cases and 2015–2019 deaths.
Approximately 2.1 percent of men and women will be diagnosed with non-Hodgkin’s lymphoma at some point during their lifetime.
It is important to remember that statistics on NHL survival rates are only estimates. The estimate is based on annual data on the number of people diagnosed with this cancer in the United States. Experts also assess survival rates every five years. As a result, the estimate may not reflect the results of improved diagnosis or therapy accessible in fewer than 5 years.
Sources:
Lymphoma is a type of blood cancer that forms from malignant cells in the lymphatic system, which is a part of the immune system and helps the body fight diseases and infection. Non-Hodgkin’s Lymphoma (NHL) consists of 85 percent of all lymphoma cases. The remaining lymphomas are considered Hodgkin’s lymphoma, which has a slightly more favorable prognosis than other lymphomas. There are many different NHL treatment options available due to the numerous subtypes, and is one of the most common cancer types. These treatment options include:
Non-Hodgkin’s Lymphoma surgery options are typically only available to patients who are diagnosed in the early stages of disease when the cancer has not spread beyond the original tumor site. The tumor is either removed during a local excision or a splenectomy for patients with marginal zone lymphoma of the spleen.
When a patient receives a Non-Hodgkin’s Lymphoma diagnosis, they may or may not have symptoms. Some treatments have harmful side effects, meaning they would cause more harm than good in a patient in the early stages of lymphoma. Watchful waiting, also known as active surveillance, is when doctors monitor a patient’s condition until signs or symptoms appear or get worse before starting treatment. This is common in patients with an indolent type of lymphoma or cancer diagnosed in the early stages.
Chemotherapy is one of the most used treatment options for all cancer types. Chemotherapy drugs kill cancer cells or prevent cancer cell division and can either be injected or taken orally. Chemotherapy drugs are often combined with other treatments in cancers, including lymphoma, which is called combination chemotherapy. Chemotherapy in lymphoma is also systemic, meaning it enters the bloodstream to reach cancer cells throughout the entire body, opposed to intrathecal chemotherapy, which only affects cancer cells near the injection site. For most subtypes, stages, aggressive, and indolent types of lymphoma, chemotherapy is almost always used or combined with another treatment.
Radiation treatment for Non-Hodgkin’s Lymphoma uses high-energy x-rays or other types of radiation to kill cancer cells by keeping them from growing. There are several types of radiation that can be used in lymphoma. External radiation therapy uses a machine to send radiation near the tumor site from outside the body. This method of radiation therapy is often used in adults with NHL or as palliative care to relieve symptoms in patients.
Proton beam radiation therapy uses streams of protons, which are particles with a positive charge, to kill tumor cells. The advantage of this method is the radiation damage is typically less to organs such as the heart or breast than other methods of radiation therapy.
Immunotherapies boost the patient’s natural immune system to fight cancer. Substances from a laboratory or naturally made in the body are injected to enhance the body’s defenses. The two most common types of immunotherapies for NHL are:
Targeted therapies in cancer treatment use drugs or other substances to identify and kill cancer cells. These therapies often cause less harmful side effects to healthy cells than chemotherapy and radiation therapy.
There are several different types of targeted therapies being developed in clinical trials that patients can access. The types of targeted therapies are listed below:
In stage 4 or metastatic non-Hodgkin’s lymphoma, treatment may include a bone marrow transplant, also known as a stem cell transplantation. Bone marrow transplant involves specialized cells called hematopoietic stem cells added to bone marrow or peripheral blood cells, then injected into the patient.
This treatment presents more risks than other standard treatments such as chemotherapy or radiation therapy. Before moving forward with a bone marrow transplant several factors, such as the patient’s age, overall health, and previous treatments are considered. There are two main types of bone marrow transplants:
Lymphoma clinical trials test the latest scientific advancements in cancer treatment for lymphoma and other cancers. Patients who choose to enroll in trials can receive cutting-edge treatment and high-quality care under the direction of scientists, doctors, and researchers. Cancer patients might gain access to promising drugs and innovative treatments long before they’re made available to the public.
Massive Bio specializes in finding advanced clinical treatments for every lymphoma type. If you’ve been diagnosed with any lymphoma subtypes, we’re here to help. If you don’t know which type of lymphoma you have, that’s okay. Additional testing can help you determine your exact diagnosis.
Sources:
Being diagnosed with any type of cancer is a stressful situation on its own. The patients might find themselves under the pressure of keeping up with the new medical terms they are hearing and lost while trying to find the best treatment option. To manage the changes in your life, one of the most effective solutions is to create a support system and delegate some of the responsibilities.
Based on the stage of your disease the treatment options and their success rate change. The overall five-year survival rate of non-Hodgkin’s lymphoma (NHL) is 73 percent. Depending on the type and stage of your cancer as well as conditions such as age, physical wellbeing, this rate might go up or down. The cancer might be completely treated, but you might still have concerns about having it back, which is called recurrence. Know that you are not alone, many cancer survivors share the same feelings. How they manage it is paying attention to their doctor’s appointments, keeping a close eye on their changing values, and making lifestyle adjustments to prevent a recurrence.
The other scenario is not having a fully successful treatment and trying to live a life with cancer. Again, many patients go through this. They keep having regular treatments, going under procedures, and taking medications. Managing the side effects of ongoing NHL treatment can be stressful as any type of cancer. Developing a close relationship with your medical team, having examined, and discussing the side effects might help you overcome or manage those life-changing effects with their help.
The definition of normal changes for each person physically, environmentally, and mentally. Each patient has a particular case defined by their specifics, so your normal might not be the same as someone else’s. Just like your normal was different from others even before diagnosis.
Starting from the diagnosis, a medical team is added to the group of people surrounding you. You develop a close relationship with the team and get used to seeing them regularly. Not having them around after the treatment might create a sense of emptiness and their absence might feel like you are out of your comfort zone, cemented by the presence of professionals. This is normal for many patients. Remember that the medical team is still there to support you.
Even when your treatment was successful and you are cancer-free, the medical team treating you will want to be in contact and want you regularly check you to see if the results are in line with their plans, and to be alert when there is a possibility of recurrence. When you go on an appointment, feel free to discuss any mental, emotional, and physical changes so that they can detect any important developments as soon as possible. You can also ask your doctor about the schedule of upcoming appointments, what kind of side effects or changes they consider normal or acceptable and so on, so that you can have a general idea of what you will go through.
When your doctor asks questions about your life after treatment, any side effects, orders some blood tests or scans, you might develop concerns about having the cancer back. The reason your doctor requests these regular visits and tests, or questions your condition is to make sure they have your situation under control. Different therapies such as radiation and chemotherapy, targeted therapy or immunotherapy create different side effects, and the side effects might go on for different periods of time. Sometimes, the medications patients use for treating a disease might cause other diseases or complications. That is why keeping up with your scheduled appointments and cooperating with your doctor is essential.
Knowing the outcome of a successful treatment can motivate you. And having an idea about the side effects might help you feel control over the course of treatment. But knowing what waits ahead is not the same as experiencing them. Therapies such as chemotherapy and radiotherapy might come with possible side effects such as,
Even when your treatment was successful and you are cancer-free, the medical team treating you will want to be in contact and want you regularly check you to see if the results are in line with their plans, monitor and control the side effects, and to be alert when there is a possibility of recurrence. When you go on an appointment, feel free to discuss any mental, emotional, and physical changes so that they can detect any important developments as soon as possible. You can also ask your doctor about the schedule of upcoming appointments, what kind of side effects or changes they consider normal or acceptable and so on, so that you can have a general idea of what you will go through.
You might start experiencing some side effects concerning your sex life due to some physical and psychological changes.
The physical side effects such as nausea or vomiting, fatigue, pain, and problems such as discomfort during intercourse, dysfunctions such as erection or premature ejaculation, vaginal dryness might create a distance towards sex, or prevent you from enjoying it.
Your idea about your physical appearance (body image), sex appeal, sex drive, self-confidence, and even your connection with sex might diminish during and after cancer treatment. The physical changes you go through such as hair loss, weight gain or scars might lead to a disconnect with your body where you feel unattractive or embarrassed. Even the uncertainty you are facing, or the financial aspect of the treatment might put pressure on you and decrease your interest in sex.
All these, along with the treatment might make you feel depressed or insecure about your sex life. To cope with the sexual side effects of cancer treatment, being prepared for them is a start. Communication among partners as well as your medical team will also be productive. Having your partner present at the doctor’s visit and letting them ask their questions and hear answers from a professional will help. If you are hospitalized, requesting time of privacy to spend time with your partner might also help. Although some might be long-lasting, most of the sexual side effects usually go away. Remember that you can always talk to your medical team in confidentiality as well as psychologists or sex counselors.
Your relationship with your family and loved ones might have shifted during the treatment. Your health might have been the center of focus for a while. The people who took over the caregiver role might find it hard to adapt to your post-treatment life as well. Although being taken care of gives the patients a sense of safety and confidence, they might not want to be treated as a patient anymore. Or the caregiver/s might want to let go of some of the tasks they overtook but do not know how to put it properly without hurting the patient’s feelings. Keep in mind that open communication will be your best friend to rearrange your relationship with them and to set the ground rules for your new normal. Your feelings about your body, identity, status, roles, or your perspective on certain matters might have been changed. Take your time to identify these according to your new normal. Ups and downs are natural. You are not supposed to feel positive or negative about anything. Be honest to yourself as well as to your loved ones, face your feelings, hear theirs, and be unreserved. Tell them what you are going through, how strong or weak you feel, what you plan or avoid, or what you expect from them so that everyone understands each other.
Although you receive treatment and know that cancer has left your body, you might have anxiety about having it back. This might put you in an alert state, where you find yourself looking for possible signs and symptoms of cancer constantly. This is where you need to manage the uncertainty. Reminding yourself that you do not have control over cancer, realizing the fears you have and not ignoring them, talking to a professional or a family member and/or a friend, learning to focus on the present and the things you have control over, finding ways to relax and including them in your daily life, learning more about your disease and developing a sense of control might help you cope with uncertainty.
One of the concerns patients have about cancer and treatment is the financial aspect of the process. Whether you are or not the provider of the house, have a backup plan, solid insurance, the cost is a big issue. That is why patients are encouraged to ask for the cost of treatment on each step of the treatment so that they know what to expect and create budgetary solutions. They should be making copies of the expenses, neatly filing them, and having a clear idea about their actual cost. Close communication with the insurance agencies, adjusting and/or looking for suitable plans are also important. Another solution to ease or help overcome the financial side effects of cancer care is learning about the institutions that are specifically founded for this very reason: helping cancer patients. These institutions include non-profit organizations, philanthropic organizations, and disease-specific societies designed to help people manage their cost of care.
Assuming the role of a caregiver comes with several serious responsibilities and changes in lifestyle. It imposes an emotional, physical, financial and social burden to the caregiver, which might lead to various complications.
Caregiver burnout. The caregivers might feel unable to help, and later go full speed on support mode, where they end up drained. They might experience fatigue, hardship to fall asleep or loss of appetite. They might also experience a shift in their emotions towards helplessness, sadness, anxiousness, guilt, anger and frustration. And when they build up, they lead to a burn out, which sometimes manifests as illness, depression, intense anxiety, irritability, resentment, or social withdrawal.
Just like a cancer patient’s, caregiver’s challenges are important and should be addressed. Here are some tips for people to manage their new life as a caregiver:
Sources:
There are many tests used for diagnosing Non-Hodgkin’s Lymphoma (NHL). Not all tests described here will be used for every person. Your doctor may consider these factors when choosing a diagnostic test:
To determine if a person has NHL, the doctor will first acquire a complete medical history. They will also do a physical examination, paying special attention to the lymph nodes, liver, and spleen. The doctor will also look for signs of infection that may cause the lymph nodes to swell and may prescribe an antibiotic. If the swelling in the lymph nodes still does not go down after antibiotic treatment, the swelling may be caused by something other than an infection. If the doctor suspects lymphoma, they will recommend a biopsy, as well as laboratory and imaging tests.
In addition to a physical examination, the following tests may be used to diagnose and stage NHL:
A biopsy is the removal of a small sample of tissue for examination under a microscope. Other tests can indicate the presence of cancer, but only a biopsy can confirm the diagnosis and determine the subtype. A core biopsy needle or surgery can be used to remove this tissue. Tissue is frequently collected from lymph nodes in the neck, under the arm, or in the groin to diagnose lymphoma. Biopsies can also be collected with a thin needle from the chest or abdomen during a computed tomography (CT) or ultrasound, or from the stomach or intestine during an endoscopy. An endoscopy is a test that allows the doctor to see inside the body with a thin, lighted, flexible tube. A biopsy of the skin may also be needed depending on which subtype of lymphoma is suspected.
In order to make a diagnosis, there must be enough tissue in the biopsy sample. Biopsies may be done by needle, such as a core biopsy or fine-needle aspiration, or by surgical biopsy. A pathologist or a hematopathologist experienced in identifying lymphoma then analyzes the materials.
A CT scan uses x-rays captured from various angles to create images of the inside of the body. A computer combines these images into a detailed, three-dimensional image that reveals any irregularities or tumors. A CT scan can be performed to determine the size of the tumor. Before the scan, a specific dye called a contrast medium is sometimes used to improve image detail. This dye can be injected directly into a patient’s vein, taken as a tablet or liquid, or both. CT scans are interpreted by a radiologist, a doctor specializing in performing imaging tests to diagnose disease. CT scans of the chest, abdomen, and pelvis can aid in the detection of cancer that has spread to the lungs, lymph nodes, spleen, and liver.
Magnetic fields, not x-rays, are used in an MRI to provide detailed body images. A magnetic resonance imaging (MRI) scan can be used to determine the tumor’s size. Before the scan, a special dye called contrast medium is administered to provide a crisper image. The scan is then interpreted by a radiologist.
A PET scan is frequently paired with a CT scan, referred to as a PET-CT scan. A PET scan is a technique for generating images of organs and tissues within the body. The patient is given a small amount of radioactive sugar material to inject into his or her body. The cells that use the most energy absorb this sugar molecule. Cancer absorbs more of the radioactive substance since it uses energy actively. The amount of radiation in the material, on the other hand, is far too low to be dangerous. The material is then detected by a scanner, which produces images of the inside of the body. A doctor can use this technique to examine the tumor’s shape as well as how much energy the tumor and healthy tissues utilize.
These two procedures to check the bone marrow are quite similar and are usually done at the same time. There is a solid and a liquid component to bone marrow. A needle is used to take a fluid sample from the bone marrow. Then, a needle is used to remove a small core of solid tissue from the bone marrow.
The material is subsequently examined by a pathologist or hematopathologist. The pelvic bone, positioned in the lower back by the hip, is a common site for bone marrow aspiration and biopsy. To numb the area, doctors usually use a local anesthetic.
Because lymphoma frequently affects the bone marrow, examining a sample of bone marrow can be helpful in diagnosing lymphoma and defining the stage. The doctor can also look for genetic alterations in the sample taken during aspiration. If a PET scan has been performed, these treatments may not be necessary for some kinds of lymphoma.
Your doctor may suggest that laboratory tests be performed on a tumor and/or bone marrow sample to identify specific genes, proteins, and other disease-specific variables. This is often referred to as biomarker testing. The results of these tests can assist you in deciding on your treatment options. There are a variety of genetic tests available:
Your doctor will discuss the results with you after the diagnostic tests are completed. If NHL is the diagnosis, this data also aids the doctor in determining the subtype and stage of the disease.
Sources:
To stage non-Hodgkin’s lymphoma, doctors perform several tests to determine the extent of the disease. This helps determine the best option for treatment. The stages of lymphoma are based on the Lugano classification, which is defined as I, II, III, and IV:
The final stage of non-Hodgkin’s lymphoma is considered stage IV. Despite many people assuming this is the NHL clinical trial stage, lymphoma clinical trials are available to patients of all stages.
One of the main factors in determining the treatment options for lymphoma is the stage. However, in some aggressive subtypes of NHL, the stage is not as much a factor. Patients are considered early-stage non-Hodgkin’s lymphoma if the disease is “limited (I or II non-bulky). Lymphoma that reaches “advanced stages” (III or IV) is often given different treatment options than patients with limited disease.
Other factors for NHL treatment include:
The International Prognostic Index (IPI) is a score that helps doctors for prognosis in addition to stages. The IPI is used for lymphoma subtypes that are aggressive and are classified as low or high-risk. Factors that determine a patient’s IPI score are:
Bulky disease is used to classify lymphomas that consist of 1 or more large tumors in the chest. These cases of lymphoma require more aggressive treatments than indolent lymphomas. For bulky disease, other prognostic factors are used in determining the right treatment option compared to other types of NHL.
NHL that continues to progress or grow larger during treatment is labeled as a progressive disease or refractory lymphoma. There are several drugs used specifically for refractory lymphomas such as Mogamulizumab, Tafasitamab, and Polatumab vedotin.
After completing treatment and there is no sign of lymphoma in the body, the patients are in remission. If the lymphoma comes back, it is called recurrent lymphoma. In most cases, this occurs within a few years of being in remission but can also happen years later. Lymphoma can return to the original site or somewhere new, where further testing needs to be done to restage the disease.
In most cases, patients will have a painless lump around the armpit, groin, or neck. Non-Hodgkin’s lymphoma causes the lymph nodes to swell up and grow over time.
In many patients, other non-Hodgkin’s lymphoma signs and symptoms include:
In stage I, NHL symptoms may not be present at all. Some patients are diagnosed when in advanced stages due to a lack of signs and symptoms in early stages. The earlier patients are diagnosed, the higher the NHL curable rate will be.
Sources:
There are more than 60 different known sub-types of non-Hodgkin’s lymphoma. It is essential to know the sub-type, as it plays a significant role in determining the treatment of non-Hodgkin’s lymphoma.
Different types of NHL are often grouped based on how they develop (by lymphocyte cell types) or how they behave (growth rate). As a result of non-Hodgkin’s lymphoma screening studies, doctors divide NHL sub-types into two categories based on the disease’s progress rate: Aggressive (fast-growing) NHL and Indolent (slow-growing) NHL.
They grow and spread slowly. In cases where NHL is not widespread in the body, does not progress, or develops gradually, the patient’s condition is closely followed; however, drug therapy or radiotherapy is not administered. Treatment is started when signs of NHL present themselves. The most common sub-type of indolent NHL in the United States is follicular lymphoma (FL).
They grow and spread quickly and have signs and symptoms that can be severe. This category accounts for about 60 percent of all NHL cases. Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive NHL sub-type.
The treatments for aggressive and indolent lymphomas are different. Regardless of how quickly they grow, all non-Hodgkin’s lymphomas can spread to other parts of the lymph system if not treated. Eventually, they can also reach other body parts, such as the brain, bone marrow, or liver.
Specialists further characterize the NHL sub-types according to cell type. The cell types of lymphoma are classified into three main groups:
Mature B-cell lymphomas (about 85-90 percent of NHL cases)
Sources:
Cancer.gov
Anything that raises a person’s chances of acquiring cancer is a risk factor. Although risk factors have a role in the development of cancer, many of them do not cause cancer. Some people who have one or more risk factors never get cancer, whereas others with none do. Knowing your risk factors and discussing them with your doctor may assist you in making better lifestyle and health-care decisions.
The specific cause of NHL is unknown, and most people diagnosed with the disease will never find out why. The following factors, on the other hand, may increase a person’s chances of developing NHL:
The risk of NHL grows as a person ages. People in their 60s and 70s are more likely to develop the most common subtypes.
Men are slightly more likely than women to develop NHL.
Specific infections are linked to certain forms of NHL. For example, an infection with the bacteria Helicobacter pylori is suspected of causing mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach. If this lymphoma is detected early enough, it can be treated with antibiotics and help it disappear. Other kinds of MALT lymphoma, such as those affecting the lungs, tear glands, and skin, can be caused by infections.
Some kinds of NHL are caused by viruses. Mononucleosis, popularly known as “mono,” is caused by the Epstein-Barr virus (EBV), which is linked to several forms of NHL. Burkitt lymphoma, lymphomas that develop after an organ transplant, and, in rare cases, other lymphomas in apparently healthy patients are among them. However, because practically everyone carries EBV, the virus is unlikely to be the sole determinant of cancer risk. NHL caused by EBV is most likely due to the body’s inability to control the infection. As a result, those who have experienced mononucleosis are not necessarily more likely to have NHL in the future. In addition, hepatitis C infection has been linked to a higher risk of splenic marginal zone lymphomas.
NHL is more common in people with immune system illnesses like HIV/AIDS, especially severe B-cell lymphomas.
Certain kinds of NHL are more likely to develop in people with autoimmune diseases such as rheumatoid arthritis and Sjögren syndrome. Some medications used to treat autoimmune illnesses have been linked to an increased risk of NHL.
NHL is more common in organ transplant recipients. This is due to the medicines that patients must take to suppress their immune systems to prevent the donated organ from being rejected.
NHL may be aggravated by previous treatment with specific medications for other cancers.
Certain substances have been linked to an increased risk of NHL. Pesticides, herbicides, and petrochemicals are examples.
Currently, there are no generally acknowledged genetic tests that can accurately detect hereditary risk factors for NHL or forecast a person’s likelihood of acquiring the disease. Clinical trials are currently being conducted to investigate these potential dangers.
The link between vaccines and lymphoma is still unknown and debatable. Vaccination with Bacillus Calmette–Guerin (BCG) has been linked to an increased risk of NHL in several studies. BCG is a tuberculosis vaccine that is used to treat bladder cancer in some circumstances. Other vaccinations, such as those for smallpox, cholera, yellow fever, influenza, measles, tetanus, and polio, have also been linked to a lower incidence of NHL.
Obesity and a diet high in fatty foods or red meat may modestly raise the risk of lymphoma, according to some inconclusive research.
Many risk factors for NHL are beyond the control of an individual. The following factors, on the other hand, can be managed:
Some women get lymphoma in the scar tissue around breast implants on a rare occasion. Breast augmentation should be a well-considered decision.
Sources:
Clinical trials focusing on Non-Hodgkin’s Lymphoma are aiming to find safe and effective new treatments, drugs or approaches to better care for the patients suffering from the disease. For these new methods to be widely available, they first need to be tested and approved. Non-Hodgkin’s lymphoma (NHL) is one of the most frequent cancers in the US, accounting for approximately 4 percent of all cancers. According to the American Cancer Society, the overall 5-year survival rate for Non-Hodgkin’s Lymphoma is 73 percent. These numbers are possible because medical science puts an enormous effort into advancement. That is why joining a clinical trial is valuable not only for the patients themselves but also anyone who is suffering from NHL.
According to the information provided by the clinicaltrials.gov, there are currently 469 clinical trials (either active, recruiting or enrolling by invitation) on Non-Hodgkin’s Lymphoma in the United States as of March 2022. There are various methods scientists are working on to improve:
Immunotherapy: The research evolving around the CAR (Chimeric antigen receptor) T-cell therapy is included under the immunotherapy studies. The patient’s healthy T-cells (a type of immune cells) are collected and engineered in the laboratory to recognize, bind to and defeat the cancer cells. In addition to four approved CAR T-cell therapies that are currently available as treatment, more is expected to be approved soon. Among the ongoing studies, several are targeting CD19, and assessing the competence of the CAR T-cell therapies for treating refectory and relapsed Non-Hodgkin’s Lymphoma.
Chemotherapy: A common treatment for all cancer patients, chemotherapy has positive results for Non-Hodgkin’s Lymphoma as well. Researchers are focusing on combining different chemotherapies and treatment methods such as immunotherapy and radiation. They are looking for ways to improve the current drugs and develop or combine new ones.
Genetic testing: Genetics is an important element in classification and diagnosis of Non-Hodgkin’s Lymphoma subtypes. Researchers are trying to find out more about the mutations (gene changes) in the development of cancer. The expectation with these studies is to identify the specific mutations to design the best treatment for each patient.
Vaccines: Especially for Non-Hodgkin’s Lymphoma in indolent nature, therapeutic vaccines are a wide area of study. Main goal is preventing or diminishing the chance of relapse of the disease after chemotherapy or targeted therapy, rather than prevention.
Targeted therapies: Targeted therapy is the most prominent and promising area of clinical trials for the Non-Hodgkin’s Lymphoma studies. The targeted drugs such as proteasome inhibitors, Histone Deacetylase (HDAC) inhibitor, Bruton Tyrosine Kinase (BTK) inhibitors, Phosphoinositide 3-kinase (PI3K) inhibitors, EZH2 inhibitor, mTOR inhibitor, nuclear export inhibitor and other agents are being carefully studied to provide new options for patients.
Bone Marrow Transplantation/Reduced-Intensity Stem Cell Transplantation (Nonmyeloablative Allogeneic Transplantation): This method is being tested both for patients that re newly diagnosed and for those already received a treatment but experienced a relapse. Current studies are looking into the procedure to determine its effectiveness for different types of lymphoma, including some subtypes of Non-Hodgkin’s Lymphoma. For preparation, the patients first receive a low dose of chemotherapy drug/s and/or radiation therapy for a while before the reduced-intensity transplant.
Supportive care/palliative care: The clinical trials also focus on diminishing the symptoms and side effects of Non-Hodgkin’s Lymphoma treatments that are already available, as improving the patients’ comfort and quality of life is one of the main concerns.
How to find clinical trials for Non-Hodgkin’s Lymphoma?
This is a question that needs to be answered in guidance of a medical team who know your medical history, your current stage and condition along with the match your case has with the requirements of a given clinical trial. Here at Massive Bio our patient advocates consist of oncology nurses, and our artificial intelligence-based clinical trial matching system can assist you to choose the best option and enroll as soon as possible. You can get a free consultation, or directly start your journey to advanced treatment options.
Sources: